Physician profile
Tanner E Woolf
NPI 1346994001
$2,828.67
in general payments reported to CMS, 2019-2025
22 companies · $1,425 in 2025
The $1,425 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $674 · 2023: $528 · 2024: $202 · 2025: $1,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,154.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,030.22 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $319.44 | 2022-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $318.67 | 2025 | Rezdiffra |
| Genzyme Corporation | $271.96 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $194.85 | 2023-2025 | Dupixent |
| Olympus America INC. | $88.53 | 2022 | |
| Intercept Pharmaceuticals, INC. | $85.29 | 2023-2025 | Ocaliva |
| Celgene Corporation | $79.69 | 2022-2023 | Zeposia |
| Pfizer INC. | $77.69 | 2023-2025 | |
| Celltrion USA INC. | $57.81 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $51.35 | 2023 | Sutab, Suflave |
| Aimmune Therapeutics, INC. | $41.61 | 2025 | Zenpep, Vowst |
| Lucid Diagnostics INC. | $35.32 | 2022-2023 | |
| Gilead Sciences, INC. | $31.07 | 2023-2025 | |
| W. L. Gore & Associates, INC. | $24.62 | 2023 | Gore Synecor Biomaterial |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $24.44 | 2025 | |
| Ardelyx, INC. | $20.29 | 2025 | Ibsrela |
| Lilly USA, LLC | $18.69 | 2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.91 | 2025 | Xifaxan |
| Qol Medical, LLC | $17.75 | 2025 | Sucraid |
| Alnylam Pharmaceuticals INC. | $14.18 | 2024 | Amvuttra |
| Digestive Care, INC. | $7.29 | 2025 | Pertzye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanner Woolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.